- Home
- OMDA vs APMD Comparison
OMDA vs APMD Comparison
Compare OMDA & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMDA | APMD |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | OMDA | APMD |
|---|---|---|
| Price | $19.75 | $26.63 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $21.73 | N/A |
| AVG Volume (30 Days) | ★ 991.1K | 359.1K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.27 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $260,210,000.00 | N/A |
| Revenue This Year | $24.96 | N/A |
| Revenue Next Year | $20.08 | N/A |
| P/E Ratio | $537.50 | ★ N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $10.28 | $20.02 |
| 52 Week High | $26.92 | $35.29 |
Technical Indicators
Market Signals| Indicator | OMDA | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 48.88 |
| Support Level | $14.39 | $24.88 |
| Resistance Level | $25.02 | $29.43 |
| Average True Range (ATR) | 1.04 | 2.61 |
| MACD | -0.36 | -0.24 |
| Stochastic Oscillator | 11.41 | 21.63 |
Price Performance
Historical ComparisonAbout OMDA Omada Health Inc.
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).